Loading...
XCSE
PEG
Market cap19mUSD
Apr 07, Last price  
0.11DKK
1D
-20.29%
1Q
-38.89%
Name

Pharma Equity Group A/S

Chart & Performance

D1W1MN
XCSE:PEG chart
No data to show
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
114.45%
Rev. gr., 5y
%
Revenues
0k
00517,00015,486,00013,252,00000620,0001,054,0000000000
Net income
-25m
L
-92,669,000-12,036,000-1,415,000-16,978,000-43,279,000-141,827,000-5,930,000-2,773,000-1,035,000177,000-7,713,000-14,417,000-32,875,0005,392,0003,479,000-24,609,000
CFO
-17m
L+478.43%
0-744,000-17,747,000-5,713,000-10,559,000-5,789,000-4,800,000-2,938,000-181,000-4,921,000-1,579,000-274,000-9,905,000-2,089,000-2,874,000-16,624,000

Profile

Pharma Equity Group A/S invests in companies with a primary focus on life sciences. It focuses on early investment in life science companies that develop technologies and therapies that enhances human health and quality of life. The company is based in Hørsholm, Denmark.
URL
https://pharmaequitygroup.com/
IPO date
Jun 25, 2003
Employees
Domiciled in
DK
Incorporated in
DK

Valuation

Title
DKK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
25,293
1,980
Unusual Expense (Income)
NOPBT
(25,293)
(1,980)
NOPBT Margin
Operating Taxes
(2,232)
(7,301)
Tax Rate
NOPAT
(23,061)
5,321
Net income
(24,609)
-807.36%
3,479
-35.48%
Dividends
Dividend yield
Proceeds from repurchase of equity
12,192
BB yield
-2.62%
Debt
Debt current
22,149
22,841
Long-term debt
8,523
876
Deferred revenue
Other long-term liabilities
25,027
Net debt
26,441
22,660
Cash flow
Cash from operating activities
(16,624)
(2,874)
CAPEX
(73)
Cash from investing activities
(73)
Cash from financing activities
17,060
3,056
FCF
(77,025)
5,350
Balance
Cash
4,231
182
Long term investments
Excess cash
4,231
182
Stockholders' equity
1,022,964
64,700
Invested Capital
64,921
68,704
ROIC
8.17%
ROCE
EV
Common stock shares outstanding
1,080,360
44,365
Price
0.43
 
Market cap
464,555
 
EV
490,996
EBITDA
(24,813)
(1,980)
EV/EBITDA
Interest
1,562
996
Interest/NOPBT